Related Experiment Video
Updated: Mar 3, 2026
04:14
Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution
Published on: April 16, 2019
12.8K
Mirtazapine-induced steatosis
Summary
This case study highlights mirtazapine-induced steatosis, a rare liver condition. Discontinuing the antidepressant mirtazapine led to rapid clinical and biochemical improvement in liver function.
Area of Science:
- Hepatology
- Clinical Pharmacology
- Psychiatry
Background:
- Mirtazapine, an antidepressant, increases central noradrenergic and serotonergic neurotransmission.
- Antidepressants are linked to elevated liver enzymes, but mirtazapine-specific steatosis reports are infrequent.
- The p450 cytochrome oxidase system metabolizes mirtazapine.
Observation:
- A 48-year-old female presented with painless jaundice, lethargy, and peripheral edema.
- Comprehensive investigations ruled out other biochemical, blood-borne, or anatomical causes for jaundice.
- The patient was taking mirtazapine for depression.
Findings:
- A diagnosis of mirtazapine-induced steatosis was made.
- Cessation of mirtazapine resulted in rapid clinical and biochemical recovery of liver function.
- The patient fully recovered after discontinuing mirtazapine.
Implications:
- This case underscores the potential for mirtazapine to cause steatosis.
- Clinicians should consider mirtazapine-induced liver injury in patients presenting with unexplained jaundice.
- Further research into the mechanisms of antidepressant-induced hepatotoxicity is warranted.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.6K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.6K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
318
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
318
01:20Antiepileptic Drugs: Potassium Channel Activators
867
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
867
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
257
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
257